Company intelligence / Profile preview

LTR Pharma Limited

Brisbane, Queensland, Australialtrpharma.com ↗

Ownership: Private
Development stage: Clinical

Overview

Currently conducting bioequivalence trials for their lead product SPONTAN, an intranasal spray for erectile dysfunction. Results from this trial are expected in the near term as of June 2024.

Therapeutic areas: Men's Health
Modalities: Small molecules (Vardenafil HCL)
Industry: Biotech

Drug pipeline

2 assets

SDS089

1 more asset in the full pipeline.

Partnerships

Mayne Pharma (production partner certified for TGA and FDA)Aptar Group (delivery device manufacturer)

Beyond the preview

Go deeper on LTR Pharma Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTR Pharma Limited.